Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAd63 ME-TRAP + MVA ME-TRAP + Matrix-M
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAd63 ME-TRAP + MVA ME-TRAP + Matrix-M is an investigational heterologous prime-boost malaria vaccine regimen developed by the **University of Oxford** in collaboration with **Novavax**. The regimen utilizes two distinct viral vectors: a chimpanzee adenovirus (ChAd63) and a Modified Vaccinia virus Ankara (MVA), both genetically engineered to express the Multiple Epitope-Thrombospondin-Related Adhesion Protein (ME-TRAP) antigen of *Plasmodium falciparum*. This antigen targets the pre-erythrocytic (liver) stage of the malaria parasite to prevent infection. The regimen is formulated with **Matrix-M** (also known as Matrix M-1), a proprietary saponin-based adjuvant developed by Novavax, which is designed to significantly enhance the magnitude and quality of the T-cell and antibody responses. This specific combination was evaluated in Phase 1 clinical trials to assess safety and immunogenicity, aiming to improve upon the efficacy of viral-vectored vaccines alone.
- Other names
- ChAd63 ME-TRAP / MVA ME-TRAP with Matrix-M AdjuvantMatrix M-1-University of Oxford-malaria
02
Targets
TRAP (Thrombospondin-related anonymous protein)
Beyond the preview
Go deeper on ChAd63 ME-TRAP + MVA ME-TRAP + Matrix-M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAd63 ME-TRAP + MVA ME-TRAP + Matrix-M.